Patents by Inventor Alar Aints

Alar Aints has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid encoding a subunit of Na,K-ATPase
    Patent number: 7829686
    Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained by alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: November 9, 2010
    Assignee: Avaris AB
    Inventors: Alexandra Treschow, Sirac Dilber, Alar Aints
  • CELLS HAVING CARDIAC GLYCOSIDE RESISTANCE
    Publication number: 20100081194
    Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained by alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.
    Type: Application
    Filed: November 25, 2009
    Publication date: April 1, 2010
    Applicant: AVARIS AB
    Inventors: ALEXANDRA TRESCHOW, SIRAC DILBER, ALAR AINTS
  • Cells having cardiac glycoside resistance
    Patent number: 7645603
    Abstract: An isolated cell having a nucleic acid construct encoding a recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g., ouabain, is disclosed. Selected amino acid substitutions in the normal human Na+, K+-ATPase ?1-subunit confers resistance to cardiac glycosides. Cardiac glycoside resistant Na+, K+-ATPase ?1-subunits may be useful as selection markers in gene therapy and research applications.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 12, 2010
    Assignee: Avaris AB
    Inventors: Alexandra Treschow, Sirac Dilber, Alar Aints
  • Cardiac glycoside resistant non-immunogenic selection marker
    Publication number: 20060228343
    Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac gIycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained b y alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.
    Type: Application
    Filed: February 13, 2004
    Publication date: October 12, 2006
    Applicant: AVARIS AB c/o Karolinska Innovations AB
    Inventors: Alexandra Treschow, Sirac Dilber, Alar Aints
  • Method for the genetic activation of cells and uses of said cells
    Publication number: 20060029583
    Abstract: Mammalian cells, normally dependent of IL-2, can be successfully transfected to express IL-2 in amounts sufficient to sustain growth without the external addition of IL-2. One cell line expressing IL-2 solely in the endoplasmatic reticulum without secretion, and one cell line capable of secretion of IL-2 have been developed and tested. Preliminary experiments using primary cells from human donors confirm the feasibility of the invention. The invention makes available gene-modified cells, methods for their production, as well as methods of the treatment of cancer and for immunostimulation.
    Type: Application
    Filed: July 1, 2005
    Publication date: February 9, 2006
    Inventors: Sirac Dilber, Alar Aints, Kyriakos Konstantinidis